Non Optimal Response to UDCA
1 clinical trials · Condition
◉ Watch Non Optimal Response to UDCA
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy (NCT06443606) | Assistance Publique - Hôpitaux de Paris | 2025-03-27 |
Track Non Optimal Response to UDCA automatically
Every clearance here is in the API, with alerts when new ones post.